.Planet Health And Wellness Organization. Weight problems as well as obese. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Ailment Threat Variable Cooperation. Worldwide patterns in underweight as well as obesity coming from 1990 to 2022: a pooled analysis of 3663 population-representative studies along with 222 million little ones, teenagers, and grownups. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Worldwide Concern Disease Collaborators. Global, local, as well as national worry of diabetes mellitus from 1990 to 2021, along with projections of incidence to 2050: a step-by-step evaluation for the Worldwide Trouble of Condition Research 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & Globe Renal Day Steerage Committee. Obesity as well as kidney disease: hidden outcomes of the prevalent. Kidney Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et al.
An organized review and meta-analysis recommends being overweight forecasts onset of persistent kidney disease in the overall population. Renal Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google.com Scholaru00c2.Jiang, Z. et cetera. Excessive weight and also severe renal illness.
Am. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Venue, J. E., do Carmo, J. M., da Silva, A.
A., Wang, Z. & Venue, M. E.
Obesity, renal problems and hypertension: mechanistic links. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Renal Condition: Improving International Results CKD Workplace Group.
KDIGO 2024 Medical Process Suggestion for the analysis as well as control of severe kidney disease. Kidney Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google Scholaru00c2.Kidney Illness: Improving Global Results Diabetes Mellitus Workplace Team. KDIGO 2022 Clinical Process Standard for diabetic issues management in constant renal condition. Renal Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google Scholaru00c2.Oshima, M. et cetera.
Early improvement in albuminuria along with canagliflozin anticipates kidney and also heart outcomes: a post hoc study from the CREDENCE trial. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.de Zeeuw, D. et cetera. Proteinuria, an aim at for renoprotection in individuals along with style 2 diabetic nephropathy: courses coming from RENAAL.
Renal Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. et cetera. Is actually a decline in albuminuria connected with kidney and also cardio protection?
A post hoc evaluation of the elevation trial. Diabetes Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic person kidney illness: a testimonial of their kidney as well as heart security. Are actually.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Muskiet, M. H.
A. et al. GLP-1 and also the kidney: coming from anatomy to pharmacology as well as results in diabetes mellitus.
Nat. Rev. Nephrol.
13, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Marso, S. P.
et cetera. Semaglutide as well as cardiovascular end results in patients along with style 2 diabetes mellitus. N.
Engl. J. Med.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Lincoff, A. M.
et cetera. Semaglutide and also cardio end results in excessive weight without diabetic issues. N.
Engl. J. Med.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Perkovic, V. et cetera.
Results of semaglutide on constant kidney health condition in individuals with kind 2 diabetic issues. N. Engl.
J. Medication. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Colhoun, H. M. et al.
Long-term kidney end results of semaglutide in weight problems as well as cardiovascular disease in the SELECT trial. Nat. Med.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Effects of semaglutide on albuminuria as well as kidney feature in people with overweight or even being overweight along with or even without type 2 diabetes: exploratory review from the STEP 1, 2, as well as 3 trials.
Diabetic issues Care 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Shaman, A. M.
et cetera. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on renal end results in clients with type 2 diabetes: pooled study of SUSTAIN 6 and also innovator. Circulation 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Apperloo, E. M. et cetera.
Effect of semaglutide on renal function across various degrees of guideline HbA1c, high blood pressure, physical body weight as well as albuminuria in SUSTAIN 6 as well as PIONEER 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et al. Dulaglutide versus the hormone insulin glargine in clients with style 2 diabetes mellitus and moderate-to-severe persistent kidney ailment (AWARD-7): a multicentre, open-label, randomised trial.
Lancet Diabetes Mellitus Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et al.
Adjustment in albuminuria as a surrogate endpoint for advancement of kidney health condition: a meta-analysis of therapy effects in randomised clinical trials. Lancet Diabetes Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Mann, J. F. E.
et al. Results of semaglutide with as well as without concomitant SGLT2 inhibitor use in attendees with style 2 diabetic issues and persistent kidney disease in the FLOW test. Nat.
Med. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et cetera. Cardiovascular, kidney and protection results with GLP-1 receptor agonists alone as well as in combination with SGLT2 preventions in style 2 diabetes: a step-by-step review and meta-analysis.
Blood circulation https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et cetera. Effectiveness and security of SGLT2 preventions along with as well as without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised measured trials. Lancet Diabetes Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Impacts of tirzepatide versus the hormone insulin glargine on renal end results in style 2 diabetes in the SURPASS-4 test: post-hoc analysis of an open-label, randomised, phase 3 test.
Lancet Diabetes Mellitus Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K.
R. et al. Physical body weight and also eGFR throughout dulaglutide procedure in type 2 diabetes mellitus and moderate-to-severe persistent kidney health condition (AWARD-7).
Diabetes Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J. L.
et cetera. Impacts of tirzepatide versus blood insulin glargine on cystatin c-based renal function: a SURPASS-4 message hoc analysis. Diabetes mellitus Care 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Diabetic Issues Care (American Diabetes mellitus Organization, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et al. Impacts of bariatric surgical treatment on renal function in overweight individuals: an organized examine and also meta study.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Bilha, S. C.
et cetera. The results of bariatric surgical procedure on kidney outcomes: an organized analysis as well as meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google Scholaru00c2.Clerte, M.
et cetera. The measured glomerular purification price (mGFR) before and 6 months after bariatric surgery: a pilot study. Nephrol.
Ther. 13, 160u00e2 $ “167 (2017 ). Articleu00c2.Google Scholaru00c2.Fawaz, S.
et cetera. Adiponectin decreases glomerular endothelial glycocalyx interruption as well as rejuvenates glomerular obstacle feature in a mouse model of style 2 diabetes. Diabetic issues 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Kidney hyperfiltration related to diabetes mellitus and also weight problems in human condition. World J.
Diabetes Mellitus 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Chagnac, A. & Friedman, A.
N. Measuring albuminuria in individuals with excessive weight: challenges of the urinary albumin-creatinine ratio. Kidney Med.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Wilding, J. P.
H. et cetera. Once-weekly semaglutide in grownups with overweight or even excessive weight.
N. Engl. J.
Medication. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Levey, A.
S. et cetera. A more precise technique to estimate glomerular purification rate coming from product creatinine: a brand new forecast formula.
Adjustment of Diet Plan in Kidney Disease Study Group. Ann. Intern.
Med. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Stevens, J.
et cetera. UHPLC-MS/MS procedure for iohexol resolution in human EDTA as well as lithium-heparin plasma, individual pee and also in goat- and also pig EDTA blood. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K. R. et al.
Efficacy as well as security of aldosterone synthase restraint along with and also without empagliflozin for chronic renal illness: a randomised, controlled, stage 2 trial. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.de Zeeuw, D.
et cetera. Efficacy of a novel prevention of general adhesion protein-1 in lessening albuminuria in people along with diabetic renal condition (CD): a randomised, placebo-controlled, period 2 trial. Lancet Diabetic Issues Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et cetera. Zibotentan in blend with dapagliflozin compared to dapagliflozin in people along with persistent kidney condition (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, professional test.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Effect of avenciguat on albuminuria in people along with CKD: 2 randomized placebo-controlled trials.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et cetera.
Sparsentan in people with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled scientific trial. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.